Sign In
Buy JNJ
$244.88
+3.88 (+1.61%)
At Close: Jun 25, 2026
Johnson & Johnson to acquire Ambrx for $2B
09:16am, Monday, 08'th Jan 2024
Johnson & Johnson (NYSE:JNJ) has announced its definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company, in an all-cash merger transaction for a total equity value o
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
09:09am, Monday, 08'th Jan 2024
The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.
J&J to buy cancer therapy developer Ambrx for $2 bln
07:40am, Monday, 08'th Jan 2024
Johnson & Johnson said on Monday it had agreed to buy drug developer Ambrx Biopharma for $2 billion to gain access to its portfolio of targeted cancer therapies.
Johnson & Johnson: Overblown Stelara Concerns Distract From Value
11:31pm, Sunday, 07'th Jan 2024
Johnson & Johnson's leading product, Stelara, is nearing the end of its exclusivity, which will likely slow down the growth of earnings per share. JNJ prioritizes growth in investments, with a focus o
5 Top Investing Resolutions for 2024
05:00am, Sunday, 07'th Jan 2024
Set yourself up for a great year -- and future -- by adding some investing promises to your New Year's resolutions list. These steps taken throughout the year could set you on the path to financial fr
Dow Darlings: Top 3 Stocks That Will Lead the Charge in 2024
03:00pm, Saturday, 06'th Jan 2024
The Dow Jones Industrial Average is up 3.64% over the past month, and technical indicators show that it could extend much further. If last year's repeat of the ‘Majestic Seven' leading the broader i
5 Relatively Secure And Cheap Dividend Stocks To Invest In - January 2024
09:30am, Saturday, 06'th Jan 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook
09:22am, Saturday, 06'th Jan 2024
Johnson & Johnson is a Dividend King focused on the creation and manufacturing of medical devices, vaccines, and medicines. Sales of Darzalex, an anti-CD38 monoclonal antibody, were $2.5 billion in th
Are defensive sectors ready to outshine growth in 2024?
07:50am, Saturday, 06'th Jan 2024
The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NA
Up To 10% Yields: My Top 10 High Dividend Yield Companies For January 2024
07:15am, Saturday, 06'th Jan 2024
High dividend yield companies are essential components within a well-balanced and diversified dividend portfolio, particularly for those seeking to generate substantial additional income via dividends
Johnson & Johnson: A Defensive Dividend King Set To Outperform The S&P 500
01:13am, Friday, 05'th Jan 2024
Johnson & Johnson is a safe and stable business with an AAA rating and a 60+ year history of dividend increases. JNJ has a strong balance sheet, generating significant free cash flow and having the re
Johnson & Johnson - One Of The World's Safest Stocks Could Return +10% Per Year
05:58pm, Thursday, 04'th Jan 2024
The Fed's potential rate cuts are causing concern in the market, as it could lead to higher inflation and negatively impact stocks. Johnson & Johnson (JNJ) is a safe investment option with a history o
January Dogs Of The Dow: 2 Buyable, 6 Watchable
12:09pm, Thursday, 04'th Jan 2024
"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.�
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
06:47pm, Wednesday, 03'rd Jan 2024
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.97, denoting a +0.63% change from the preceding trading day.
Revenge of the Boring Stocks! Dividends Are Sexy Again.
04:00pm, Wednesday, 03'rd Jan 2024
It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.
